Nov 13, 2024 9:05am EST Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
Nov 12, 2024 8:00am EST Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Nov 4, 2024 7:00am EST Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
Nov 1, 2024 7:00am EDT Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
Oct 24, 2024 8:00am EDT Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
Oct 17, 2024 8:00am EDT Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
Oct 16, 2024 8:00am EDT Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)
Oct 8, 2024 8:30am EDT Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
